A phase ii multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy

Marek Trnĕny, Gregor Verhoef, Martin J.S. Dyer, Dina Ben Yehuda, Caterina Patti, Miguel Canales, Andrés Lopez, Farrukh T. Awan, Paul G. Montgomery, Andrea Janikova, Anna M. Barbui, Kazimierz Sulek, Maria J. Terol, John Radford, Anna Guidetti, Massimo Di Nicola, Laure Siraudin, Laurence Hatteville, Sandrine Schwab, Corina OpreaAlessandro M. Gianni

Research output: Contribution to journalArticle

18 Scopus citations

Fingerprint Dive into the research topics of 'A phase ii multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy'. Together they form a unique fingerprint.

Medicine & Life Sciences